Samsung Biologics has launched S-DUAL, its own dual antibody platform for future drug development, further strengthening its global competitiveness edge in contract drug development and manufacturing services.

The company said on Thursday it recently completed a patent application for the platform technology, which will facilitate applications to the development and production of various next-generation multi-antibody and other therapeutics in the future.

S-DUAL, a technology that combines two antibodies together, is known to outdo existing dual antibodies in terms of safety and production efficiency. Samsung Biologics expects that S-DUAL will greatly enhance its service lineup across the contract development and manufacturing business.

By Kim Si-gyun and Minu Kim

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]